S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
GOOGL   1,217.77 (+0.17%)
AMZN   1,736.43 (+0.26%)
CGC   18.86 (-2.93%)
NVDA   186.53 (+0.29%)
MU   44.86 (-0.53%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
AMD   30.53 (+2.62%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
PRI   121.47 (-0.18%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
GOOGL   1,217.77 (+0.17%)
AMZN   1,736.43 (+0.26%)
CGC   18.86 (-2.93%)
NVDA   186.53 (+0.29%)
MU   44.86 (-0.53%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
AMD   30.53 (+2.62%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
PRI   121.47 (-0.18%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
Log in

Sanofi Stock Price, News & Analysis (NYSE:SNY)

$44.89
-0.06 (-0.13 %)
(As of 10/14/2019 04:00 PM ET)
Today's Range
$44.79
Now: $44.89
$45.04
50-Day Range
$42.58
MA: $44.58
$46.60
52-Week Range
$40.00
Now: $44.89
$47.11
Volume662,572 shs
Average Volume1.31 million shs
Market Capitalization$112.41 billion
P/E Ratio14.34
Dividend Yield2.58%
Beta0.67
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone33-1-53-77-44-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$39.60 billion
Cash Flow$4.93 per share
Book Value$26.11 per share

Profitability

Net Income$4.28 billion

Miscellaneous

EmployeesN/A
Outstanding Shares2,504,138,000
Market Cap$112.41 billion
Next Earnings Date10/31/2019 (Confirmed)
OptionableOptionable

Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.


Sanofi (NYSE:SNY) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Tuesday, February 26th. Stockholders of record on Wednesday, May 8th will be paid a dividend of $1.7395 per share on Friday, May 31st. This represents a dividend yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi SA (NYSE:SNY) released its earnings results on Monday, July, 29th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.67 by $0.07. The company had revenue of $8.63 billion for the quarter, compared to analysts' expectations of $8.42 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The company's quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.25 EPS. View Sanofi's Earnings History.

When is Sanofi's next earnings date?

Sanofi is scheduled to release their next quarterly earnings announcement on Thursday, October 31st 2019. View Earnings Estimates for Sanofi.

How can I listen to Sanofi's earnings call?

Sanofi will be holding an earnings conference call on Thursday, October 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Sanofi issued on next quarter's earnings?

Sanofi updated its FY 2019 earnings guidance on Monday, July, 29th. The company provided earnings per share (EPS) guidance of $5.74-5.74 for the period.

What price target have analysts set for SNY?

9 equities research analysts have issued 12 month target prices for Sanofi's stock. Their forecasts range from $50.00 to $52.00. On average, they expect Sanofi's stock price to reach $51.00 in the next twelve months. This suggests a possible upside of 13.6% from the stock's current price. View Analyst Price Targets for Sanofi.

What is the consensus analysts' recommendation for Sanofi?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sanofi.

What are Wall Street analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:
  • 1. According to Zacks Investment Research, "Sanofi’s focus on streamlining operations and pursuing business development deals is encouraging. Sanofi’s Specialty Care segment, particularly, is on a strong footing with recent FDA approvals of new drugs Libtayo and Cablivi, and Dupixent for its second indication in asthma. Dupixent could prove to be an important growth driver. The performance of the Vaccines and Consumer Healthcare franchises has also improved of late. Sanofi’s R&D pipeline is strong and it has delivered important results with several positive data read-outs and the achievement of regulatory milestones this year. However, headwinds include weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. Shares have outperformed the industry in the past six months." (8/29/2019)
  • 2. HC Wainwright analysts commented, "We used a discounted cash flow (DCF)-based approach to valuing 2.0% terminal growth rate, 7.3% discount rate and 22% effective tax rate. Our assumptions assign a 90% probability of launch to DARZALEX in smoldering MM." (2/28/2019)

Has Sanofi been receiving favorable news coverage?

News headlines about SNY stock have been trending negative this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sanofi earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Sanofi.

Who are some of Sanofi's key competitors?

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Johnson & Johnson (JNJ), Gilead Sciences (GILD), AT&T (T), General Electric (GE), Bank of America (BAC), Merck & Co., Inc. (MRK), Exxon Mobil (XOM), AbbVie (ABBV), Alibaba Group (BABA) and Pfizer (PFE).

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:
  • Mr. Olivier Brandicourt, CEO & Director (Age 62)
  • Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 53)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik, Head of Investor Relations

Who are Sanofi's major shareholders?

Sanofi's stock is owned by many different of retail and institutional investors. Top institutional investors include Foundation Resource Management Inc. (0.01%), Cullinan Associates Inc. (0.00%), Pacer Advisors Inc. (0.00%), Keystone Financial Planning Inc. (0.00%), Thomasville National Bank (0.00%) and Crossmark Global Holdings Inc. (0.00%). View Institutional Ownership Trends for Sanofi.

Which major investors are selling Sanofi stock?

SNY stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Foundation Resource Management Inc., Stonebridge Capital Management Inc., Pacer Advisors Inc., Carroll Financial Associates Inc., Courier Capital LLC and First Hawaiian Bank. View Insider Buying and Selling for Sanofi.

Which major investors are buying Sanofi stock?

SNY stock was bought by a variety of institutional investors in the last quarter, including Cullinan Associates Inc., Old North State Trust LLC, Keystone Financial Planning Inc., Capital Asset Advisory Services LLC and Thomasville National Bank. View Insider Buying and Selling for Sanofi.

How do I buy shares of Sanofi?

Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $44.89.

How big of a company is Sanofi?

Sanofi has a market capitalization of $112.41 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. View Additional Information About Sanofi.

What is Sanofi's official website?

The official website for Sanofi is http://www.sanofi.com/.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]


MarketBeat Community Rating for Sanofi (NYSE SNY)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  434 (Vote Outperform)
Underperform Votes:  540 (Vote Underperform)
Total Votes:  974
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel